Chemical Compound with Triazine Group and Production Method

ChangeBridge: Patent Apps - Therapeutics (A61P)

Published March 26th, 2026

Detected March 27th, 2026

Summary

The USPTO has published a patent application (US20260085087A1) for a chemical compound comprising a triazine group and its production method. The application relates to novel nucleotides and oligonucleotides with modified phosphate groups, potentially useful in diagnostics, gene therapy, and treating bacterial and viral diseases, including COVID-19.

View original document View source feed page

What changed

This document is a publication of a patent application (US20260085087A1) by the USPTO, detailing a chemical compound with a triazine group and its production method. The invention focuses on nucleotides and oligonucleotides with modified phosphate groups, aiming to provide compounds with therapeutic potential and an improved production method. Potential applications include cytological studies, pathogen diagnostics, gene therapy, and treatment of bacterial and viral diseases, specifically mentioning COVID-19.

As this is a patent application publication, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, companies in the pharmaceutical and biotechnology sectors may wish to review the application for potential intellectual property insights, competitive intelligence, or future licensing opportunities. The filing date was October 13, 2021, and the publication date is March 26, 2026.

Source document (simplified)

← USPTO Patent Applications

CHEMICAL COMPOUND COMPRISING A TRIAZINE GROUP AND METHOD FOR PRODUCING SAME

Application US20260085087A1 Kind: A1 Mar 26, 2026

Inventors

Maxim Sergeevich KUPRYUSHKIN, Timofei Dmitrievich ZHARKOV, Ilya Sergeevich DOVYDENKO, Oleg Vladimirovich MARKOV

Abstract

A chemical compound having a triazine group and a method for production thereof are related to novel compounds and methods for production thereof in nucleotide chemistry. In particular, the present invention relates to nucleotides and oligonucleotides comprising a modified phosphate group, and to the method for production thereof. The present invention may be used in cytological studies, in DNA- or RNA-containing pathogen diagnostics, in gene therapy as well as in treating various bacterial and viral diseases, including COVID-19. The objective of the present invention is to provide compounds having a therapeutic potential as well as to develop the available method for production thereof.